Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Berlin - Delayed Quote EUR

Zealand Pharma A/S (22Z.BE)

Compare

95.10

-0.70

(-0.73%)

At close: February 24 at 7:35:18 PM GMT+1

Zealand Pharma AS (ZLDPF) Q4 2024 Earnings Call Highlights: Strong Cash Position and Obesity ...

Zealand Pharma AS (ZLDPF) reports significant advancements in obesity treatments and a robust cash reserve, while navigating FDA hurdles and increased R&D expenses.

GuruFocus.com 3 days ago

ZEAL.CO

NVO
Zealand Pharma steadfastly upholds amylin-based obesity drug strategy

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and development timeline.

Pharmaceutical Technology 4 days ago

ZEAL.CO
Zealand Pharma convenes its Annual General Meeting 2025

Company Announcement – No. 3 / 2025 Zealand Pharma convenes its Annual General Meeting 2025 Notice to convene the Annual General Meeting 2025 of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company"). The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on: Thursday, March 27, 2025 at 3:00 pm (CET) The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in person (hy

GlobeNewswire 4 days ago

ZLDPF
Correction: Zealand Pharma Announces Financial Results for the Full Year 2024

Company announcement – No. 2 / 2025 Correction includes 2024 Annual Report attached in iXBRL format. Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant clinical advancement across differentiated obesity pipeline, while building the foundation for accelerated growth in the years to come Positive results with long-acting amylin analog petrelintide in 16-week Phase 1b trial and advancement into large, comprehensive Phase 2b trial in people wit

GlobeNewswire 4 days ago

ZLDPF
Zealand Pharma Announces Financial Results for the Full Year 2024

Company announcement – No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant clinical advancement across differentiated obesity pipeline, while building the foundation for accelerated growth in the years to come Positive results with long-acting amylin analog petrelintide in 16-week Phase 1b trial and advancement into large, comprehensive Phase 2b trial in people with overweight or obesity Positive topline results with GLP-1/GLP-2

GlobeNewswire 4 days ago

ZLDPF
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results

Press Release – No. 3 / 2025 Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results Copenhagen, Denmark, February 13, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it will host a conference call on February 20, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the

GlobeNewswire 11 days ago

ZLDPF
High Growth Tech Stocks To Watch In February 2025

As global markets navigate a landscape marked by mixed corporate earnings and competitive pressures in the AI sector, U.S. stocks have experienced volatility, with notable fluctuations in tech-heavy indices like the Nasdaq Composite. In this context, identifying high-growth tech stocks requires careful consideration of companies that can adapt to rapid technological advancements and maintain robust performance despite market uncertainties.

Simply Wall St. 17 days ago

ZLDPF
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Company announcement – No. 1 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, January 13, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securit

GlobeNewswire last month

ZLDPF
High Growth Tech Stocks to Watch in January 2025

As we enter January 2025, global markets have shown mixed performance, with the S&P 500 and Nasdaq Composite closing out a strong year despite recent fluctuations. Economic indicators such as the Chicago PMI and revised GDP forecasts highlight ongoing challenges for small-cap companies, but positive trends in jobless claims provide some optimism. In this environment, identifying high-growth tech stocks requires focusing on companies with robust innovation capabilities and adaptability to...

Simply Wall St. last month

ZLDPF
Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Press Release – No. 2 / 2025 Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity Copenhagen, Denmark, January 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Steven R. Smith, MD, has joined Zealand Pharma as Senior Global Medical Advisor – Obesity, as of January 1, 2025. Steven will report to David Kendall, Chief

GlobeNewswire last month

ZLDPF
Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

Press Release – No. 1 / 2025 Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th Copenhagen, Denmark, January 6, 2025 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will present an overview of the company at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA at 2:15 p.m. PT (11:15

GlobeNewswire last month

ZLDPF
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Company announcement – No. 52 / 2024 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, 25 December 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 23 December 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder:

GlobeNewswire last month

ZLDPF
U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

Company announcement – No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA concluded that Zealand Pharma’s application did not meet the full requirements for substantial evidence to establish the efficacy and safety of the to-be-marketed dose of glepaglutide.Zealand Pharma will continue the dialogue with the FDA to align on the path toward obtaining regulatory approval in the U

GlobeNewswire 2 months ago

ZLDPF
2 Weight Loss Stocks That Are Screaming Buys in December

With drugs like Novo Nordisk's Wegovy becoming household names over the last couple of years, it's no surprise that there are quite a few opportunities to invest in the burgeoning market for weight-loss medicines. Zealand Pharma (OTC: ZLDP.F) is a biotech with a pipeline that's full of promising clinical-stage weight-loss programs, among other indications. In particular, its lead anti-obesity program, a molecule called survodutide, is in phase 3 clinical trials right now, and it's unique in the sense that no weight-loss drug on the market right now utilizes the exact same mechanism of action.

Motley Fool 2 months ago

LLY

ZEAL.CO
Exploring Top High Growth Tech Stocks For Potential Portfolio Enhancement

In recent weeks, global markets have experienced mixed performances with major U.S. indexes like the S&P 500 and Nasdaq Composite continuing to hit record highs, while smaller-cap indices such as the Russell 2000 saw declines after a period of outperformance. This divergence highlights the ongoing rally in growth stocks, particularly within sectors like information technology and consumer discretionary, which have shown significant gains amid varied economic indicators such as job growth...

Simply Wall St. 2 months ago

ZLDPF

6645.TW
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Zealand Pharma announces that the first participant has been enrolled in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity.The Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment.Completion of enrollment into ZUPREME-1 is expected in th

GlobeNewswire 2 months ago

ZLDPF
Zealand Pharma to participate in the Jefferies London Healthcare Conference

Press Release – No. 11 / 2024 Zealand Pharma to participate in the Jefferies London Healthcare Conference Copenhagen, Denmark, November 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Jefferies London Healthcare Conference at 9:30 a.m. GMT (10:30 a.m. CET) on Thursday, November 21, 2024. A liv

GlobeNewswire 3 months ago

ZLDPF
Exploring High Growth Tech Stocks In November 2024

Global markets have recently experienced significant shifts, with U.S. stocks rallying to record highs following a Republican electoral sweep, leading to expectations of accelerated earnings growth and reduced regulatory burdens. Amidst these developments, the small-cap Russell 2000 Index has shown impressive gains, highlighting the potential opportunities within high-growth tech stocks as investors seek companies that can thrive under favorable economic policies and lower corporate taxes.

Simply Wall St. 3 months ago

1415.HK

ZLDPF
Zealand Pharma AS (ZLDPF) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Financial ...

Zealand Pharma AS (ZLDPF) showcases promising trial results and strategic partnerships while navigating high R&D expenses and regulatory hurdles.

GuruFocus.com 3 months ago

ZEAL.CO
Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates

Zealand Pharma AS (ZLDPF) delivered earnings and revenue surprises of 9.68% and 75.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

ZEAL.CO

Performance Overview

Return	22Z.BE	OMX Copenhagen 25 Index
YTD	-1.55%	+2.92%
1-Year	+48.25%	-3.49%
3-Year	+607.59%	+10.74%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Zealand Pharma A/S (22Z.BE)

Zealand Pharma AS (ZLDPF) Q4 2024 Earnings Call Highlights: Strong Cash Position and Obesity ...

Zealand Pharma steadfastly upholds amylin-based obesity drug strategy

Zealand Pharma convenes its Annual General Meeting 2025

Correction: Zealand Pharma Announces Financial Results for the Full Year 2024

Zealand Pharma Announces Financial Results for the Full Year 2024

Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results

High Growth Tech Stocks To Watch In February 2025

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

High Growth Tech Stocks to Watch in January 2025

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

2 Weight Loss Stocks That Are Screaming Buys in December

Exploring Top High Growth Tech Stocks For Potential Portfolio Enhancement

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Zealand Pharma to participate in the Jefferies London Healthcare Conference

Exploring High Growth Tech Stocks In November 2024

Zealand Pharma AS (ZLDPF) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Financial ...

Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates

Performance Overview